IP Library Granted Patent US 7,470,668
Granted Patent B2
US 7,470,668 · App. 11/210,631 · Granted Dec 30, 2008

Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,470,668
App. No.
11/210,631
Granted
Dec 30, 2008
Kind
B2
Abstract

A method of using an osteocrin (Ostn) or a NPR-C specific Ostn peptide derivative for increasing osteogenesis in a mammal comprising administering a therapeutically effective amount of said Ostn or NPR-C specific Ostn peptide derivative to the mammal.

Claims (17)

1. A method of using an osteocrin (Ostn) or a NPR-C specific Ostn peptide derivative comprising an NM2 motif for increasing osteogenesis in a mammal suffering from osteoporosis, comprising administering a therapeutically effective amount of said Ostn or NPR-C specific Ostn peptide derivative to the mammal.

2. The method as recited in claim 1 , wherein an Ostn is used.

3. The method as recited in claim 2 , wherein the Ostn comprises the amino acid sequence of SEQ ID NO: 1.

4. The method as recited in claim 3 , wherein the Ostn consists of the amino acid sequence of SEQ ID NO: 1.

5. The method as recited in claim 1 , wherein a NPR-C specific Ostn peptide derivative comprising the NM2 motif is used.

6. The method as recited in claim 5 , wherein the NPR-C specific Ostn peptide derivative comprises the amino acid sequence of SEQ ID NO: 41.

7. The method as recited in claim 6 , wherein the NPR-C specific Ostn peptide derivative consists of the amino acid sequence of SEQ ID NO: 41.

8. The method as recited in claim 5 , wherein the NPR-C specific Ostn peptide derivative comprises the amino acid sequence of SEQ ID NO: 69.

9. The method as recited in claim 5 , wherein the NPR-C specific Ostn peptide derivative comprises the amino acid sequence of SEQ ID NO: 65.

10. The method as recited in claim 5 , wherein the NPR-C specific Ostn peptide derivative comprises the amino acid sequence of SEQ ID NO: 66.

11. The method as recited in claim 5 , wherein the NPR-C specific Ostn peptide derivative consists of the amino acid sequence of SEQ ID NO: 65.

12. The method as recited in claim 5 , wherein the NPR-C specific Ostn peptide derivative comprises the amino acid sequence of SEQ ID NO: 57.

13. The method as recited in claim 5 , wherein the NPR-C specific Ostn peptide derivative comprises the amino acid sequence of SEQ ID NO: 62.

14. The method as recited in claim 1 , wherein said mammal is a human.

15. The method as recited in claim 2 , wherein the Ostn comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12.

16. The method as recited in claim 5 , wherein the natural NPR-C specific Ostn peptide derivative comprises an amino acid sequence from the group consisting of SEQ ID NO: 29, SEQ ID NO: 33, SEQ ID NO: 37, SEQ ID NO: 45, SEQ ID NO: 49 and SEQ ID NO: 53.

17. The method as recited in claim 5 , wherein the NPR-C specific Ostn peptide derivative comprises an amino acid sequence from the group consisting of SEQ ID NO: 12, SEQ ID NO: 32, SEQ ID NO: 36, SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 48, SEQ ID NO: 52, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, and SEQ ID NO: 68.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2016
From: ALEXION PHARMA HOLDING
To: ALEXION PHARMACEUTICALS, INC.
Reel/Frame 037600/0246 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2013
From: ALEXION PHARMA INTERNATIONAL SARL
To: ALEXION HOLDING B.V.
Reel/Frame 030894/0591 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2013
From: ALEXION HOLDING B.V.
To: ALEXION PHARMA HOLDING
Reel/Frame 030894/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2013
From: ENOBIA CANADA LIMITED PARTNERSHIP
To: ALEXION PHARMA INTERNATIONAL SARL
Reel/Frame 029670/0011 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 23, 2012
From: ENOBIA PHARMA INC.
To: ENOBIA CANADA LIMITED PARTNERSHIP
Reel/Frame 027752/0067 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2005
From: LANCTOT, CHRISTIAN; MOFFATT, PIERRE; THOMAS, GETHIN
To: ENOBIA PHARMA INC.
Reel/Frame 016864/0247 →